Ken Griffin Ocugen, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.98 - $1.95 $21,952 - $43,680	-22,400 Reduced 6.03%	348,900 $345,000
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.98 $2,950 - $4,950	-2,500 Reduced 0.67%	371,300 $575,000
Q1 2024 May 15, 2024	SELL	$0.5 - $1.83 $44,150 - $161,589	-88,300 Reduced 19.11%	373,800 $613,000
Q4 2023 Feb 14, 2024	SELL	$0.36 - $0.57 $12,456 - $19,722	-34,600 Reduced 6.97%	462,100 $263,000
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $7,800 - $12,090	-19,500 Reduced 3.78%	496,700 $198,000
Q2 2023 Aug 14, 2023	SELL	$0.45 - $0.88 $22,185 - $43,384	-49,300 Reduced 8.72%	516,200 $278,000
Q1 2023 May 15, 2023	SELL	$0.82 - $1.33 $283,802 - $460,313	-346,100 Reduced 37.97%	565,500 $480,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.87 $323,898 - $545,666	291,800 Added 47.08%	911,600 $1.19 Million
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $392,000 - $694,400	224,000 Added 56.59%	619,800 $1.1 Million

125

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $204M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.